IP Verse

Neutralization Of Inhibitory Pathways In Lymphocytes - EP3405495

The patent EP3405495 was granted to Innate Pharma on Feb 24, 2021. The application was originally filed on Jan 20, 2017 under application number EP17702315A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3405495

INNATE PHARMA
Application Number
EP17702315A
Filing Date
Jan 20, 2017
Status
Granted And Under Opposition
Jan 22, 2021
Grant Date
Feb 24, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOIBERG PSNov 24, 2021ZWICKERADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2013034559
DESCRIPTIONUS5229275
DESCRIPTIONUS5567610
DESCRIPTIONUS8206709
DESCRIPTIONWO03101485
DESCRIPTIONWO2006121168
DESCRIPTIONWO2007005874
DESCRIPTIONWO2008156712
DESCRIPTIONWO2009014708
DESCRIPTIONWO2009101611
DESCRIPTIONWO2009114335
DESCRIPTIONWO2010077634
DESCRIPTIONWO2011066389
DESCRIPTIONWO2012145493
DESCRIPTIONWO2013019906
DESCRIPTIONWO2015085847
DESCRIPTIONWO9928748
INTERNATIONAL-SEARCH-REPORTWO2008009545
INTERNATIONAL-SEARCH-REPORTWO2016041945
OPPOSITIONWO2008009545

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- JENKINS R W ET AL, "Mechanisms of resistance to immune checkpoint inhibitors", BRITISH JOURNAL OF CANCER, (20180102), vol. 118, pages 9 - 16-
EXAMINATION- PARDOLL D M, "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS. CANCER, (20120401), vol. 12, pages 252 - 264-
EXAMINATION- RIBAS A & WOLCHOK J, "Cancer immunotherapy using checkpoint blockadde", SCIENCE, (20180323), vol. 359, pages 1350 - 1355, XP055537294
OPPOSITION- "AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology", (20150424), URL: https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-innate-pharma-global-collaboration-immuno-oncology-24042015.html#, XP055883061-
OPPOSITION- "FOURTH CLINICAL TRIAL OPENED WITH MONALIZUMAB (IPH2201)", Press Release Innate Pharma, (20151217), URL: https://www.innate-pharma.com/sites/default/files/151217_trial_combo_mona_cetux_0.pdf, (20220124), XP055883051-
OPPOSITION- "Innate Pharma Company Presentation", Jefferies Healthcare Conference, (201506), URL: https://www.jefferies.com/CMSFiles/Jefferies.com/files/Innate%20Pharma.pdf, XP055883693-
OPPOSITION- Kim J W, Eder J P, " Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types", Oncology, us , (20141111), vol. 28, no. 11_Suppl. 3, ISSN 0890-9091, XP055199598-
OPPOSITION- "NEW DATA PRESENTED AT AACR SUPPORT THE RATIONALE FOR COMBINATION TREATMENT WITH MONALIZUMAB AND DURVALUMAB", PRESS RELEASE Innate Pharma, (20160418), URL: https://www.innate-pharma.com/sites/default/files/160418_nkg2a_pd1-pdl1_ev.pdf, (20220125), XP055883666-
OPPOSITION- Pezo R. C., P.L. Bedard, "Chapter 1 - Definition: Translational and Personalised Medicine, Biomarkers, Pharmacodynamics", ESMO Handbook of Translational Research, (20150101), pages 1 - 11, XP055883110-
OPPOSITION- Sola C. et al., "NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD-1/PD-L1 inhibitors in a preclinical model", (20160101), URL: https://www.innate-pharma.com/sites/default/files/iph_poster_aarc2016_monalizumab.pdf, (20220124), XP055883104-
OPPOSITION- Jose Luis Perez-Gracia, Sara Labiano, Maria E Rodriguez-Ruiz, Miguel F Sanmamed, Ignacio Melero, Philip K Darcy, David S Ritchie, "Orchestrating immune check-point blockade for cancer immunotherapy in combinations", Current Opinion in Immunology, (20140401), vol. 27, doi:10.1016/j.coi.2014.01.002, ISSN 09527915, pages 89 - 97, XP055200525
OPPOSITION- Bernardo Marie, Tolstykh Tatiana, Zhang Yu-An, Bangari Dinesh S., Cao Hui, Heyl Kerstin A., Lee Joon Sang, Malkova Natalia V., Malley Katie, Marquez Eladio, Pollard Jack, Qu Hui, Roberts Errin, Ryan Sue, Singh Kuldeep, Sun Fangxian, Wang Emma, Bahjat Keith, Wiederschain Dmitri, Wagenaar Timothy R., "An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy", OncoImmunology, (20210101), vol. 10, no. 1, doi:10.1080/2162402X.2021.1881268, XP055883698
OPPOSITION- L. Seymour, A. Tinker, H. Hirte, N. Wagtmann, P. Dodion, "O3.2 * Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A", Annals of Oncology, (20150301), vol. 26, no. suppl 2, doi:10.1093/annonc/mdv081.2, ISSN 0923-7534, page ii3, XP055384900
OPPOSITION- Sullivan L. C., Clements C. S., Rossjohn J., Brooks A. G., "The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity", TISSUE ANTIGENS, DK , (20081101), vol. 72, no. 5, doi:10.1111/j.1399-0039.2008.01138.x, ISSN 0001-2815, pages 415 - 424, XP055883109
OPPOSITION- D. B. Johnson, "Nivolumab in melanoma: latest evidence and clinical potential", Therapeutic advances in medical oncology, (20150101), vol. 7, no. 2, doi:10.1177/1758834014567469, pages 97 - 106, XP055704675
OPPOSITION- L. Ruggeri, E. Urbani, P. Andre, A. Mancusi, A. Tosti, F. Topini, M. Blery, L. Animobono, F. Romagne, N. Wagtmann, A. Velardi, "Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells", Haematologica, IT , (20160501), vol. 101, no. 5, doi:10.3324/haematol.2015.135301, ISSN 0390-6078, pages 626 - 633, XP055306808

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents